Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Cardiovascular Diseases
  • Trastuzumab

abstract

  • The cumulative incidence of CE at 6 years was slightly higher with the addition of trastuzumab; however, the late development of CE is infrequent. Trastuzumab (in the context of anthracycline- and taxane-based therapy) continues to have a favorable benefit-risk ratio.

publication date

  • February 20, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4980566

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.61.8413

PubMed ID

  • 26392097

Additional Document Info

start page

  • 581

end page

  • 7

volume

  • 34

number

  • 6